Short Interest in PainReform Ltd. (NASDAQ:PRFX) Drops By 13.3%

PainReform Ltd. (NASDAQ:PRFX) was the target of a large decrease in short interest in March. As of March 13th, there was short interest totaling 68,090 shares, a decrease of 13.3% from the February 26th total of 78,499 shares. Currently, 25.8% of the shares of the stock are short sold. Based on an average trading volume of 28,070 shares, the short-interest ratio is currently 2.4 days.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of PainReform in a report on Thursday, January 22nd. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has an average rating of “Sell”.

PainReform Stock Performance

Shares of PainReform stock opened at $2.11 on Thursday. The stock has a market cap of $850,330.00, a price-to-earnings ratio of 0.00 and a beta of 0.55. The stock has a 50 day moving average price of $2.92 and a 200-day moving average price of $4.49. PainReform has a one year low of $1.80 and a one year high of $17.95.

PainReform (NASDAQ:PRFX) last issued its quarterly earnings results on Thursday, March 26th. The company reported ($0.98) earnings per share (EPS) for the quarter.

About PainReform

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations.